Study of Immunotherapy to Treat Advanced Prostate Cancer

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Ipilimumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Advanced prostate cancer

• At least 1 bone metastasis

• Testosterone < 50 ng/dl

• Prior treatment with docetaxel

Exclusion Criteria:

• Brain metastasis

• Autoimmune disease

• Known HIV, Hep B, or Hep C infection

• More than 2 prior systemic anticancer regimens for prostate cancer

• Prior treatment on BMS CA180227 for prostate cancer